Oncolytics Biotech Inc. announced data demonstrating that its investigational candidate pelareorep transforms immunologically inactive liver tumors into a 'hot' phenotype susceptible to immune-based therapies. The positive clinical data strengthens the company's narrative of pelareorep as a backbone therapy.